The Role of Hormone Receptor Expression and Hormonal Therapy (Estrogen and Progesterone) in the Management and Prognosis of Meningiomas in Females: A Systematic Review

Abstract

Meningioma is the primary central nervous system
tumour with the highest recorded prevalence. Research
on meningiomas has shown an association with
hormone receptor expression, but the underlying
pathophysiologic mechanisms remain unclear. This
systematic review presents the available information on
the role of progesterone and estrogen in meningioma’s
pathogenesis, prognosis, and treatment. The study
used the Preferred Reporting Items for Systemic Review
and MetaAnalysis (PRISMA) 2020 guidelines. The
authors searched and downloaded relevant published
articles from the following databases; PubMed, PubMed
Central (PMC), MEDLINE, the Cochrane Library, and
Google Scholar. The downloaded articles were screened
using set eligibility criteria and appropriate quality
appraisal tools and subsequently relevant data was
extracted using standardized questionnaires. Based on
the papers reviewed, progesterone receptor expression
in meningioma is associated with significantly more
favourable prognostic factors and treatment outcomes
while a negative correlation exists between overall
survival and the presence of estrogen receptors. In
conclusion, analysing hormone receptor expression in
meningioma appears necessary for targeted hormonal
and endocrine therapy. A suitable reference population
must also be defined in future extensive prospective
multi-centre and multi-national clinical studies